Diffusion of particular recommendations, addressing each of the elements on the use of LAI antipsychotics, will increase clinicians’ perceived competence. It is going to also assist to raise the percentage of sufferers to whom LAI antipsychotics is going to be offered by psychiatrists as a therapeutic solution. The objective of those suggestions is to propose a prescription framework to clinicians for the usage of a distinct formulation of antipsychotics (LAI) in diverse therapeutic indications and certain clinical circumstances. The aim will be to allow clinicians to supply one of the most suitable pharmaceutical approaches towards the individuals and to facilitate the use of LAI antipsychotics in clinical practice. The suggestions presented right here from a consensus-based recommendations methodology (Formal Consensus Suggestions) arebased on scientific information and also the consensus of a panel of authorities.MethodsQuestionnaire developmentInitially, we performed an analysis as well as a literature evaluation regarding the indications as well as the use of LAI antipsychotics. A literature search applying the key phrases “antipsychotic”, “neuroleptic”, “first-generation antipsychotic”, “atypical antipsychotic”, “second-generation antipsychotic”, “long-acting injectable”, “depot”, “depot neuroleptic” was performed in PubMed and EMBASE to locate all of the relevant research published. Further references were identified from http:www.fda.gov and http: www.ema.europa.eu. Data from all of those sources was discussed and an overview from the present evidence has been graded and summarized utilizing the French National Authority for Overall health (HAS) “levels of evidence” criteria [16]. Following this first step, the scientific committee (PML, LS, MA, Pc, SG, SL) made a questionnaire consisting of 32 questions that covered 539 therapeutic selections. The 32 queries have been regrouped into 3 places PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/21310042 that had been judged as critical: Target-population: Description of the different indications of your LAI antipsychotics and in the most proper period on the illness to introduce the treatment. Prescription and use: Decision of your molecule, techniques of introduction, precise tactics depending on the psychiatric disorder or comorbidities, and therapy monitoring. Precise population: Use of LAI antipsychotics in pregnant women, elderly sufferers, subjects inside a precarious situation, and subjects possessing to become treated in a prison establishment. This questionnaire was created to be completed by an experts’ panel. The time essential for its administration was estimated at about 3 hours. In the time of development, each of the LAI antipsychotics accessible in France were proposed as therapeutic selections (Table 1). They were regrouped into two categories: Long-acting injectable first-generation antipsychotics (LAI FGA). Long-acting injectable second-generation antipsychotics (LAI SGA). This artificial separation FGASGA just isn’t consensual as a result of their heterogeneous profiles of efficacyLlorca et al. BMC Psychiatry 2013, 13:340 http:www.biomedcentral.com1471-244X13Page three ofTable 1 LAI antipsychotics out there in France (when the survey was completed)LAI second-generation antipsychotics LAI first-generation antipsychotics Risperidone microsphere Olanzapine pamoate Haloperidol decanoate Zuclopenthixol decanoate Flupentixol decanoate Fluphenazine decanoate MedChemExpress ML264 Pipotiazine palmitateNote: as paliperidone palmitate had a marketing authorization date soon after the development of those suggestions, it couldn’t be taken into account.Professional selectionThe Scientific Committee (Appendix 1) sel.